Original research

The prevalence of color vision deficiency in the northeast of Iran

Hassan Hashemi a, Mehdi Khabazkhoob b,c, Reza Pakzad a, Abbasali Yekta d, Javad Heravian d, Payam Nabovati e, Hadi Ostadimoghaddam f,*

a Noor Research Center for Ophthalmic Epidemiology, Noor Eye Hospital, Tehran, Iran
b Department of Medical Surgical Nursing, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
c Noor Ophthalmology Research Center, Noor Eye Hospital, Tehran, Iran
d Department of Optometry, School of Sciences, Mashhad University of Medical Sciences, Mashhad, Iran
e Department of Optometry, School of Rehabilitation Sciences, Iran University of Medical Sciences, Tehran, Iran
f Refractive Errors Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Received 7 November 2016; revised 29 April 2017; accepted 14 May 2017
Available online 9 June 2017

Abstract

Purpose: To determine the prevalence of color vision deficiency (CVD) in the northeast of Iran.

Methods: This cross-sectional, population-based study was conducted in Mashhad, in the northeast of Iran. Multistage cluster sampling was used for selecting the participants. After preliminary screening, the subjects underwent a complete ophthalmic examination. The examination included the measurement of visual acuity, refraction, and slit-lamp biomicroscopy. The Farnsworth D-15 test was used to detect CVD. The color vision test was done with the best optical correction.

Results: Of the 4453 invitees, 3132 participated in the study (response rate: 70.4%). The overall prevalence of CVD in this study was 13.93% [95% confidence interval (CI): 12.44–15.41]. The prevalence of CVD in males and females was 15.85% (95% CI: 13.26–18.44) and 12.96% (95% CI: 11.22–14.71), respectively. The most prevalent types of CVD were tritanopia (6.96%; 95% CI: 5.84–8.08), deuteranopia (3.92%; 95% CI: 3.14–4.70) and tritanomalous (2.21%; 95% CI: 1.55–2.86), respectively. According to the results of logistic regression, the odds of having protanopia were higher in females than males [Odds ratio (OR) = 4.80; 95% CI: 1.20–19.18]. The odds of having deuteranopia were lower in females than males (OR = 0.52; 95% CI: 0.35–0.76). The odds of having CVD were lower in 16–30 (OR = 0.52; 95% CI: 0.37–0.73) and higher in 46–60 (OR: 1.41; 95% CI: 1.01–1.97) year age groups compared to 7–15 year age group. The odds of having tritanopia in 16–30 and 46–60 year age groups was 0.56 (95% CI: 0.35–0.90) and 1.79 (95% CI: 1.19–2.67) compared to 7–15 year age groups, respectively.

Conclusion: The prevalence of CVD was high in this study, especially in males and people over 46 years of age. Planning for involvement of ocular disease control programs in health care systems can be helpful in the reduction of CVD and improving the quality of life in affected patients.

Copyright © 2017, Iranian Society of Ophthalmology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords: Color vision deficiency; Prevalence; Population based study; Farnworth D-15

Introduction

Color vision deficiency (CVD) is one of the most important visual disorders affecting a considerable percentage of the population.1 CVD may be congenital or acquired.2,3 Congenital forms of CVD occur as a result of dysfunction in the cone cells, and the patient experiences different problems in
The acquired type of CVD has various subtypes caused by different diseases. The type of the defect depends on what part of the visual system, including the retina, optic nerve, and visual cortex, is affected by the disease or injury.5,7

The prevalence of congenital color blindness is different in various parts of the world. For example, 8% of men and 0.4% of women are color blind in western countries.1 The prevalence of CVD is 4–6.5% in Japan and China,2–4 4% in African countries,9 7.3% in Turkey,4 and 2.9–11% in Saudi Arabia.10,11 However, the prevalence of acquired color blindness varies according to occupation, sex, and age, and has been reported to be 5–20% in different studies.1,12–15

Although no treatment has been found for this reason, some color lenses and gene therapy are available for the patients, but the results are not always satisfactory. For this reason, color blind people usually experience disorders in daily activities, learning, and skill acquisition for certain professions and therefore cannot have certain jobs.16 As a result, they have a decreased quality of life and experience socioeconomic problems.17

Few studies have addressed the prevalence of CVD in Iran, and the available studies have covered different areas with different results. A study in Shahrroud1 reported a prevalence of 4.4% and 10.1% for congenital and acquired CVD, and other studies in Tehran,1,18 the schools of Zanjan,19 and the general population of Qazvin20 reported a prevalence of 8.8%, 8.07%, and 3.49% for CVD, respectively, indicating differences in the prevalence of this disease in different parts of the country. Considering the importance of CVD, there is a need for comprehensive information on its status to make effective plans for it. Population-based studies can meet this need and provide health policy makers with a better perspective of this disease. Therefore, we conducted this study to evaluate the prevalence of CVD in Mashhad, the second largest city in Iran.

Methods

This cross-sectional, population-based study was conducted in the urban population of Mashhad. The target population of the study was all residents of Mashhad aged above 1 year. The population of Mashhad was 2,451,712 according to a 2005 population census. Stratified cluster sampling was used to select the participants proportional to the population of different districts of Mashhad (municipality districts were considered as strata). A number of clusters were selected in each district proportional to the number of households. In total, 120 clusters were randomly selected from blocks determined by Statistics Center of Khorasan Razavi, and the first house number in each cluster was considered as the cluster head. In each cluster, sampling was systematically continued for up to 10 households. First, the interviewers introduced themselves, explained the importance of this project for the household, and completed a demographic questionnaire. Then they were invited to attend the Optometry Clinic of Mashhad University of Medical Sciences for complete ophthalmic examination. Sampling was systematically continued in a clockwise manner for up to 10 households. If a household was not willing to participate or was not present in the house, the next house number was invited. All participants were transported to the Clinic by the research team.

The Ethics Committee of Mashhad University of Medical Sciences approved the study protocol, which was conducted in accord with the tenets of the Declaration of Helsinki. All participants signed a written informed consent.

First, the uncorrected visual acuity was measured with an E Snellen chart. Then objective refraction was performed using an auto refractometer (TOPCON, KR-8000, Japan), and the results of auto refraction were refined with retinoscopy (HEINE BETA). In the next step, the best far and near optical correction was determined using subjective refraction, and near and distance best corrected visual acuity were recorded.

The Farnsworth D-15 test was used to assess color vision in all individuals aged over 7 years in similar light conditions with optical correction (near optical correction was used in presbyopic participants). The participants had only 5 min to finish the test. However, those aged above 50 years were given a little more time due to their increased reaction time.

Participants younger than 6 years of age, participants with a previous history of intraocular surgeries, and those who did not complete the color vision test were excluded from the study.

Statistical analysis

In this study, the prevalence of CVD is reported as percentage along with 95% confidence interval (CI). In calculating CIs, we used binomial distribution when the distribution was not normal. The design effect was considered for the calculation of standard error. The effect of cluster sampling was regarded when calculating the CI. Simple and multiple logistic regressions were used to evaluate the relationship of CVD and its types with age and sex. A p-value of less than 0.05 was considered statistically significant.

Results

Of the 4453 invitees, 3132 subjects participated in the study (response rate: 70.4%). After applying the exclusion criteria, eventually there were 2628 subjects available for this analysis. The mean age of the participants was 31.54 ± 16.9 years (range, 7–90 years), and 1751 of them (66.6%) were female.

The prevalence of CVD was 13.93% (95% CI: 12.44–15.41) in the study population, 15.85% (95% CI: 13.26–18.44) in men, and 12.96% (95% CI: 11.22–14.71) in women. Tritanopia was the most common type of CVD with a prevalence of 6.96% (95% CI: 5.84–8.08), followed by deuteranopia, and tritanomalous with a prevalence of 3.92% (95% CI: 3.14–4.70), and 2.21% (95% CI: 1.55–2.86), respectively.
According to the results of this study, the highest prevalence of CVD was observed in the age groups: over 60 years (20.93%; 95% CI: 13.63–28.23), 46–60 years (20.53%; 95% CI: 16.31–24.75), and 7–15 years (15.64%; 95% CI: 12.84–18.43), respectively. Regarding the type of CVD, tritanopia was the most prevalent type in all age groups. The prevalence of other types of CVD has been shown in Table 1.

Table 1 shows the results of simple and multiple logistic regressions for CVD and its types with respect to the age and sex. We considered the results of multiple model for interpretation of the data. According to this, the odds of protanopia in females were 4.80 (95% CI: 1.20–19.18) of its odds in males, while, the odds of deuteranopia were lower in females than males (0.52; 95% CI: 0.35–0.76).

By considering the 7–15 years age group as the reference group, the odds of having CVD in 16–30 and 46–60 year age groups were 0.52 (95% CI:0.37–0.73) and 1.41 (95% CI: 1.01–1.97), respectively. Also, the odds of having tritanopia in 16–30 year age group were lower than its odds in 7–15 year age group (0.56; 95% CI:0.35–0.90). The odds of having tritanopia in 46–60 year age group were higher than its odds in 7–15 year age group (1.79; 95% CI:1.19–2.67).

Discussion

Congenital CVD is a common genetic disorder affecting many patients worldwide. Its hereditary type is a recessive X-linked disorder and is therefore more prevalent in men than women. This disease causes a marked limitation and disability in the patients, and usually affects a considerable percentage of people depending on the population and its characteristics.

The results of our study showed a prevalence of 13.93% for CVD in the study population, which is higher than other countries (Table 3). The prevalence of CVD has been reported to be 4.02% in Spain, 7.33% in Turkey, 10.3% in the USA, and 2.56% in Italy.

The findings of our study not only contradicted the notion that the incidence of CVD is lower in Asian countries as compared with western countries, but also showed a higher prevalence in comparison with many Asian and Middle East countries. For example, the prevalence of CVD has been reported to be 5.28% in India, 2.93% in Saudi Arabia, and 8.72% in Jordan. In addition to ethnic varieties, there may be other reasons for this difference. The first reason could be the tool used for the assessment of color vision. The Ishihara's test was used in the studies conducted in Turkey, Spain, and Italy while we used the Farnsworth D-15 test. The Farnsworth D-15 is the second most commonly used test for the detection of CVD after the Ishihara's test, and has a great capability for detecting CVDs, especially blue-yellow deficiency. Since the Ishihara's test can only detect red-green deficiency and cannot detect blue-yellow deficiency, some CVDs may be missed in studies that use the Ishihara's test, and therefore, their prevalence is underestimated. The findings of our study are in line with the results of a study that used the Farnsworth D-15 test and reported a prevalence of 14.7%.

Another finding of our study was the higher prevalence of CVD in men than women. The prevalence of color blindness was 15.85% in men and 12.96% in women. Although other studies have also reported a higher prevalence of the disease in men versus women, the prevalence of color blindness in our female participants was higher than other studies. Although this finding is in line with the findings of study, other previous studies have not supported this finding.

There may be two reasons for the difference. The first is the test that was used to assess color vision. Most studies used the Ishihara's test, but the ones whose results were similar to our study used the Farnsworth D-15 test. The second reason which is more important may be lack of differentiation between congenital and acquired cases in this study, causing overestimation in the prevalence of CVD.

Table 1

The prevalence (95% confidence interval) of color vision deficiency (CVD) and its different types in the study population by sex and age groups.

| Age Group | Protanopia (%(95%CI)) | Deuteranopia (%(95%CI)) | Tritanopia (%(95%CI)) | Protanomalous (%(95%CI)) | Deuteranomalous (%(95%CI)) | Tritanomalous (%(95%CI)) | Color blindness (%(95%CI)) |
|-----------|-----------------------|-------------------------|-----------------------|-------------------------|---------------------------|--------------------------|-----------------------------|
| Total (n = 2628) | 0.80(0.45–1.15) | 3.92(3.14–4.77) | 6.96(5.84–8.08) | 0.34(0.09–0.59) | 0.38(0.12–0.64) | 2.21(1.55–2.86) | 13.93(12.44–15.41) |
| Sex | Male (n = 877) | 0.23(0.06–0.91) | 5.74(4.18–7.23) | 7.75(5.85–9.66) | 0.46(0.01–0.9) | 0.68(0.14–1.23) | 1.82(0.83–2.82) | 15.85(13.26–18.44) |
| Female (n = 1751) | 1.09(0.6–1.55) | 3.03(2.21–3.84) | 6.57(5.22–7.91) | 0.29(0.01–0.81) | 0.23(0.07–0.76) | 2.46(1.16–3.14) | 12.96(11.22–14.71) |
| Age | 7–15 (n = 582) | 0.86(0.11–1.61) | 5.53(3.72–7.27) | 7.22(5.14–9.3) | 0.17(0.03–1.18) | 1.03(0.08–1.98) | 2.41(1.15–3.66) | 15.64(12.84–18.43) |
| 16–30 (n = 773) | 0.26(0.06–1.04) | 1.94(0.98–2.9) | 4.14(2.68–5.6) | 0.65(0.08–1.21) | 0.13(0.02–0.92) | 1.68(0.76–2.6) | 8.54(6.48–10.59) |
| 31–45 (n = 691) | 0.72(0.09–1.36) | 4.63(3.06–6.2) | 5.64(3.82–7.46) | 0.14(0.02–1.03) | 0 | 2.32(1.19–3.44) | 12.88(10.34–15.42) |
| 46–60 (n = 453) | 1.55(0.43–2.66) | 4.42(2.34–6.49) | 12.14(9.06–15.22) | 0.44(0.06–3.12) | 0.44(0.11–1.78) | 2.21(0.77–3.65) | 20.53(16.31–24.75) |
| >60 (n = 129) | 1.55(0.39–6.15) | 3.1(0.18–6.03) | 11.63(5.88–17.38) | 0 | 0.78(0.11–5.45) | 3.88(0.66–7.09) | 20.93(13.63–28.23) |

CI: Confidence interval.

The 95%CI was calculated by binomial distribution.
The type of CVD depends on whether it is congenital or acquired. Red-green deficiency is more common in patients with congenital CVD, and yellow-blue deficiency is more common in patients with acquired CVD.

In our study, tritanopia was the most common type of CVD with a prevalence of 6.96%, followed by deuteranopia, and tritanomalous with a prevalence of 3.92%, and 2.21%, respectively. This order was also true for male and female participants. It seems that the higher prevalence of tritanopia in our study is due to the use of the Farnsworth D-15 test that can detect CVDs, especially blue-yellow deficiency. Our results are in agreement with the findings of other studies that used this test, and this can be a support for our justification.

The association between age and CVD was another finding of our study. The odds of having CVD were lower in 16–30 and higher in 46–60 year age groups compared to 7–15 year age group. It seems that the prevalence of CVD decreases until midlife and sharply increases thereafter. This pattern also holds for tritanopia. Individuals in older ages have a higher risk for developing ocular pathologies like cataract, glaucoma, retinal disorders, systemic diseases (e.g., diabetes), and more exposure to environmental factors which have influence on acquired color deficiency. All of these increase the risk of acquired CVD. This issue can explain the observed associations in this study.

A strong point of our study is its large sample size as we evaluated about 2628 people. Therefore, our results are valid and have a high generalizability. Moreover, our sampling made it possible to include all age groups into the study to assess the relationship between age and the prevalence of CVD, which has been evaluated in a few studies.

Another strong point of this study is the use of the Farnsworth D-15 test instead of Ishihara's test, which enables us to explain our different findings, as well. In contrast to Ishihara's test that can only detect red-green deficiency, the Farnsworth D-15 can detect blue-yellow deficiency as well. This is especially important in the statistics of acquired CVD because most acquired cases have blue-yellow deficiency which may be missed on the Ishihara's test.

A limitation of this study is the lack of differentiation between acquired and congenital CVD, which may itself explain some differences with the results of previous studies. Some studies only reported the prevalence of congenital CVD and reported the prevalence of acquired and congenital CVD separately, which could lead to different results.

Another limitation of this report is that, we could not evaluate the association between some age-related ocular pathologies like cataract and glaucoma with CVD. The association between CVD and age may be due to the association between CVD and age-related ocular pathologies. Unfortunately, we were not able to explore such associations with the available data. Also, there may be other potential confounders that its effects have not been controlled in this study.

However, this study is very valuable due to its large sample size and population-based design, and its results can be used in health system policies.

### Table 2

| Protanopia Deuteranopia Tritanopia Protanomalous Deuteranomalous Tritanomalous | OR (95%CI); p-value | OR (95%CI); p-value | OR (95%CI); p-value | OR (95%CI); p-value | OR (95%CI); p-value | OR (95%CI); p-value | OR (95%CI); p-value |
|---|---|---|---|---|---|---|---|
| Simple | Sex Female/Male | 4.8 (1.2–19.18); 0.027 | 0.52 (0.35–0.76); 0.001 | 0.84 (0.6–1.17); 0.298 | 0.62 (0.15–2.59); 0.516 | 0.33 (0.08–2.36); 0.345 | 0.79 (0.62–1); 0.055 |
| Multiple regressions | Age 7–15 | 1.56 (0.15–15.1); 0.151 | 0.34 (0.19–0.62); 0.01 | 0.56 (0.35–0.89); 0.014 | 0.8 (0.4–1.53); 0.247 | 0.93 (0.57–1.52); 0.369 | 0.5 (0.36–0.71); 0.012 |
| | Age 16–30 | 0.8 (0.4–1.53); 0.247 | 0.93 (0.57–1.52); 0.369 | 0.5 (0.36–0.71); 0.012 | 0.51 (0.35–0.76); 0.001 | 0.62 (0.15–2.59); 0.516 | 0.33 (0.08–2.36); 0.345 |
| | Age 31–45 | 0.8 (0.4–1.53); 0.247 | 0.93 (0.57–1.52); 0.369 | 0.5 (0.36–0.71); 0.012 | 0.51 (0.35–0.76); 0.001 | 0.62 (0.15–2.59); 0.516 | 0.33 (0.08–2.36); 0.345 |
| | Age 46–60 | 0.8 (0.4–1.53); 0.247 | 0.93 (0.57–1.52); 0.369 | 0.5 (0.36–0.71); 0.012 | 0.51 (0.35–0.76); 0.001 | 0.62 (0.15–2.59); 0.516 | 0.33 (0.08–2.36); 0.345 |
| | Age >60 | 0.8 (0.4–1.53); 0.247 | 0.93 (0.57–1.52); 0.369 | 0.5 (0.36–0.71); 0.012 | 0.51 (0.35–0.76); 0.001 | 0.62 (0.15–2.59); 0.516 | 0.33 (0.08–2.36); 0.345 |

CI: Confidence interval; OR: Odds ratio.

*H. Hashemi et al. / Journal of Current Ophthalmology 31 (2019) 80–85*
### The prevalence of color vision deficiency (CVD) in different countries and other cities in Iran.

| Location | Age | Sample size | Type of color blindness | Screen test | Prevalence |
|----------|-----|-------------|-------------------------|-------------|------------|
|          |     |             |                         | Male% | Female% | Total% |
| Saudi Arabia, 1996 | 11–18 | 410 | congenital red-green color vision defects | Ishihara test | — | — | 2.93 |
| Turkey, 2002 | 20–26 | 941 | Congenital Color Blindness | Ishihara test | — | — | 7.33 |
| India, 2012 | — | 2674 | Congenital Color Blindness | Ishihara test | 8.73 | 1.69 | 5.28 |
| India, 2013 | 6–15 | 1028 | Color vision deficiency | Ishihara test | 11.36 | 3.03 | — |
| Philippines, 2010 | 12–16 | 1258 | Color vision deficiency | Ishihara and | — | — | 5.17 |
| Nepal, 2012 | 19–26 | 215 | Color vision deficiency | Ishihara test | — | — | 5.58 |
| Nepal, 2012 | Medical student | 120 | Congenital color vision defects | Ishihara test | — | — | 5.83 |
| Korea, 1989 | Middle school | 9438 | Congenital color vision defects | Hardy-Rand-Rittler | 5.9 | 0.44 | 3.15 |
| Nepal, 2006 | 10–19 | 964 | Color vision deficiency | Ishihara test | 3.8 | 0 | 1.86 |
| Italy, 1992 | — | 3133 | red-green color vision defects | Ichikawa plates | 2.56 | 0.1 | 1.05 |
| Jordan, 2001 | university students | 1418 | congenital red/green color blindness | Ishihara test | 8.72 | 0.33 | 1.62 |
| America, 1985 | All ages | 2499 | Color vision deficiency | — | 20.4 | 1.8 | 10.8 |
| Spain, 1990 | student | 392 | red/green color blindness | Ishihara test | 4.02 | 0.46 | 2.04 |
| Tehran, Iran, 2013 | 7–12 | 2160 | Color vision deficiency | Yang vision tester | 3.5 | 1 | 2.2 |
| Shahroud, Iran, 2013 | 40–64 | 5102 | Color vision deficiency | Farnsworth D-15 | 16.6 | 13.3 | 14.7 |
| Tehran, Iran, 1996 | 12–14 | 2058 | Color vision deficiency | Ishihara test | 4.51 | 0.19 | 4.71 |
| Zahedan, Iran, 2012 | primary school | 1000 | red/green color blindness | Ishihara test | 1.6 | 0.2 | 0.9 |
| Mashhad, Iran 2009 | (current study) | All ages | 2628 | Color vision deficiency | Farnsworth D-15 | 15.85 | 12.96 | 13.93 |

In conclusion, the prevalence of CVD was high in Mashhad, especially in males and people over 46 years of age. Planning for involvement of ocular disease control programs in health care systems can be helpful in the reduction of CVD and improving the quality of life in affected patients.

### References

1. Jafarzadeh P, Hashemi H, Emamian MH, et al. Color vision deficiency in a middle-aged population: the Shahroud Eye Study. *Int Ophthalmol*. 2014;34(5):1067–1074.
2. Chan E, Mao WS. Colour-blindness among the Chinese. *Br J Ophthalmol*. 1950;34(12):744.
3. Sato S. Statistical observations on congenital abnormalities in colour vision in Japan. *Acta Soc Ophthalmol Jpn*. 1955;34:2227–2230.
4. Cittirik M, Acaroglu G, Batman C, Zilelioglu O. Congenital color blindness in young Turkish men. *Ophthalmic Epidemiol*. 2005;12(2):133–137.
5. Saito A, Mikami A, Hasegawa T, et al. Behavioral evidence of color vision deficiency in a protanomalia chimpanzee (Pan troglodytes). *Primates*. 2003;44(2):171–176.
6. Cruz EM, Cerdana HGS, Cabrera AMB, et al. Prevalence of color vision deficiency among male high-school students. *Philipp J Ophthalmol*. 2010;35(1):20–24.
7. Shah A, Hassan R, Fareed M, Afzal M. Prevalence of red-green color vision defects among Muslim males and females of Manipur, India. *Iran J Public Health*. 2013;42(1):16–24.
8. Rajavi Z, Sabbaghi H, Baghini AS, Yaseri M, Sheibani K, Norouzi G. Prevalence of color vision deficiency and its correlation with ambylopia and refractive errors among primary school children. *J ophthalmic & Vis Res*. 2015;10(2):130.
9. Birch J. Worldwide prevalence of red-green color deficiency. *J Opt Soc Am A Opt Image Sci Vis*. 2012;29(3):313–320.
10. Ouzoubi EP. Prevalence of congenital red-green color vision defects in Arab boys from Riyadh, Saudi Arabia. *Ophthalmic Epidemiol*. 1996;3(3):167–170.
11. Voke J, Voke P. Congenital dyschromatopsias among Saudi Arabians. *Saudi Med J*. 1980;1:209–214.
12. Delporo WT, O'Neill H, Casson E, Hovis J. Aviation-relevant epidemiology of color vision deficiency. *Aviat Space Environ Med*. 2005;76(2):127–133.
13. Heydarian S, Mahjoob M, Gholami A, Veysi S, Mohammadi M. Prevalence of color vision deficiency among arc welders. *J Optom*. 2017;10(2):130–134.
14. Simunovic MP. Acquired color vision deficiency. *Surv Ophthalmol*. 2016;61(2):152–155.
15. Winters J, Matchinski T, Squier K. Acquired color vision deficiency among visually impaired adults attending a vision rehabilitation clinic. *Investig Ophthalmol Vis Sci*. 2014;55(3):4161–4161.
16. Pramanik T, Sherpa MT, Shrestha R. Color vision deficiency among medical students: an unnoticed problem. *Nepal Med Coll J*. 2010;12(2):131–132.
17. Post RH. Population differences in red and green color vision deficiency: a review, and a query on selection relaxation. *Soc Biol*. 1982;29(3-4):299–315.
18. Modarres M, Mirsamadi M, Peyman GA. Prevalence of congenital color deficiencies in secondary-school students in Tehran. *Int Ophthalmol*. 1996;20(4):221–222.
19. Bagherzadeh MR, Ghodamei M, Hosseini M. Color blindness in male students in guidance schools (Zanjan-2002). *Iran J Ophthalmol*. 2006;19(1):55–62.
20. Khalaj M, Barikani A, Mohammadi M. Prevalence of color vision deficiency in Qazvin. *Zahedan J Res Med Sci*. 2014;16(1):91–93.
21. Fareed M, Anwar MA, Afzal M. Prevalence and gene frequency of color vision impairments among children of six populations from North Indian region. *Genes & Dis*. 2015;2(2):211–218.
22. Espinda SD. Color vision deficiency: a learning disability? *J Learn Disabil*. 1973;6(3):163–166.
23. Floris G, Murgia E, Sanciu MG. Frequency of Color Blindness in Sardinia (Italy). *Bulletins et Mémoires de la Société d’anthropologie de Paris; 1992:105–110.
24. Kim HB, Lee SY, Choe JK, Lee JH, Ahn BH. The incidence of congenital color deficiency among Koreans. *J Korean Med Sci*. 1989;4(3):117–120.
25. Niroula DR, Saha CG. The incidence of color blindness among some school children of Pokhara, Western Nepal. *Nepal Med Coll J*. 2010;12(1):48–50.
26. Rebato E, Calderon R. Incidence of red-green color blindness in the Basque population. *Anthropol Anz.* 1990;48(2):145–148.
27. Collins JG. Prevalence of selected chronic conditions: United States, 1990-1992. *Vital Health Stat.* 1997;10(194):1–89.
28. Al-Aqtum MT, Al-Qawasmeh MH. Prevalence of colour blindness in young Jordanians. *Ophthalmologica.* 2001;215(1):39–42.
29. Dain SJ. Clinical colour vision tests. *Clin Exp Optometry.* 2004;87(4-5):276–293.
30. Kaur N, Singh K. Comparative review of color blindness in different ethnic populations. *J Evol Med Dent Sci.* 2013;1(2):6977–6981.
31. Adam A, Doron D, Modan R. Frequencies of protan and deutan alleles in some Israeli communities and a note on the selection-relaxation hypothesis. *Am J Phys Anthrop.* 1967;26(3):297–305.
32. Amiri M, Kelishadi R, Motlagh ME, et al. Prevalence study of clinical disorders in 6-year-old children across Iranian provinces: findings of Iranian national health assessment survey. *J Res Med Sci Off J Isfahan Univ Med Sci.* 2012;17(7):596–601.
33. Momeni-Moghaddam H, Ng JS, Robabi H, Yaghubi F. Color vision deficiency in Zahedan, Iran: lower than expected. *Optom Vis Sci.* 2014;91(11):1372–1376.
34. Applegate RA, Adams AJ, Cavender JC, Zisman F. Early color vision changes in age-related maculopathy. *Appl Opt.* 1987;26(8):1458–1462.
35. Javitt JC, Wang F, West SK. Blindness due to cataract: epidemiology and prevention. *Annu Rev Public Health.* 1996;17:159–177.
36. Niwa Y, Muraki S, Naito F, Minamiikawa T, Ohji M. Evaluation of acquired color vision deficiency in glaucoma using the Rabin cone contrast test. *Investig. Ophthalmol Vis Sci.* 2014;55(10):6686–6690.
37. Sample PA, Weinreb RN, Boynton RM. Acquired dyschromatopsia in glaucoma. *Surv Ophthalmol.* 1986;31(1):54–64.
38. Thiadens AA, Roosing S, Collin RW, et al. Comprehensive analysis of the achromatopsia genes CNGA3 and CNGB3 in progressive cone dystrophy. *Ophthalmology.* 2010;117(4), 825–830 e821.
39. Feitosa-Santana C, Paramei GV, Nishi M, Gualtieri M, Costa MF, Ventura DF. Color vision impairment in type 2 diabetes assessed by the D-15d test and the Cambridge Colour Test. *Ophthalmic Physiol Opt.* 2010;30(5):717–723.
40. Attarchi MS, Labbafinejad Y, Mohammadi S. Occupational exposure to different levels of mixed organic solvents and colour vision impairment. *Neurotoxicol Teratol.* 2010;32(5):558–562.
41. Guest M, D’Este C, Attia J, et al. Impairment of color vision in aircraft maintenance workers. *Int Arch Occup Environ Health.* 2011;84(7):723–733.
42. Willmann G, Ivanov IV, Fischer MD, et al. Effects on colour discrimination during long term exposure to high altitudes on Mt Everest. *Br J Ophthalmol.* 2010;94(10):1393–1397.
43. Pramanik T, Khatiwada B, Pandit R. Color vision deficiency among a group of students of health sciences. *Nepal Med Coll J.* 2012;14(4):334–336.